Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
about
Pharmacotherapy of systemic sclerosisVascular Remodelling and Mesenchymal Transition in Systemic SclerosisCellular Therapies in Systemic Sclerosis: Recent ProgressTreatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases.Pulmonary hypertension and right heart dysfunction in chronic lung disease.Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients.Cardiovascular involvement in autoimmune diseases.Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding.Ocular findings in patients with systemic sclerosis.Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.Engineering dextran-based scaffolds for drug delivery and tissue repair.Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunctionVascular leak is a central feature in the pathogenesis of systemic sclerosis.Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.Vascular regeneration: engineering the stem cell microenvironment.The challenges of dialysis in systemic sclerosis: between the devil and the deep blue sea?Infection and autoimmune disease.Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis.The vascular microenvironment and systemic sclerosis.Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A.Circulating angiopoietin and Tie-2 levels in systemic sclerosis.Vascular endothelial growth factor (VEGF), mast cells and inflammation.Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis.A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol
P2860
Q24629481-7FA78104-4B7B-4E4D-AC46-173D6FA71820Q26749091-3963CAF5-D80E-40D2-81C4-9667BCD724C9Q28080323-9A5FB607-3AB7-49D2-BCA3-41132E0B45B7Q30318407-60614373-EBCD-489B-9B8C-547ABD3D9B08Q30432299-58BDD5C3-3A3C-49C9-A770-D45A63299F0BQ34068022-BD518625-C24F-43EE-A40F-74F3D639DF65Q34081242-6904CD3A-24D4-49F2-90DC-585C1FDF8422Q34729999-9949E2F7-28D6-4EB8-8C69-BD4174CA9C57Q34768694-4E95325B-249D-473A-9336-19AD8315F4A1Q35685660-D7BACBF7-6ABB-4FAE-9463-DC521CDD2F66Q36205757-78B3322B-D8C3-4258-81C3-92DCB3344AC8Q36590463-84FBB21F-488D-4C65-8516-6DD86EE63B40Q36806259-ECEFB12E-2C48-4C21-ABE2-69E1D83033BEQ37327062-774DC8D3-F5D0-4059-90F9-CDBD52C38C70Q37479819-DCB88D1A-98B3-4E8C-B10C-F8D45396024CQ37556213-DD42DB11-0044-4625-956C-DDF03843EF01Q38027432-4200DCC9-6F7D-4A0F-9594-A9F1459D437AQ39907084-DB322569-2354-473A-BDC8-11A783C87978Q40355666-2CDD4088-96E0-46D7-BC80-EBCA58616B6AQ41863950-EA2ACBC3-C492-4B93-8654-CDD054122484Q42492897-2E91BE8C-4247-46CE-8DA5-BB5014B7519EQ44016255-62779ABE-975E-4C07-B5F7-B160B7740CE8Q44817598-4820FA28-9A97-4857-BB33-E01A7734C0D4Q46754465-A20825DA-5855-4A89-851E-5E0CCB84FE44Q47852702-23276194-0EAD-4E87-B1FF-69A008414727Q58736202-9A68CB62-0EC5-4400-97E3-B681A953FE16
P2860
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@en
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@nl
type
label
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@en
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@nl
prefLabel
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@en
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@nl
P2093
P2860
P356
P1433
P1476
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
@en
P2093
J H W Distler
S Guiducci
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEN267
P478
47 Suppl 5
P577
2008-10-01T00:00:00Z